|
|
Procarbazine
and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas:
a phase II study
Alba A. Brandes, Mario Ermani, Sergio
Turazzi, Elvira Scelzi, Franco Berti, Pietro
Amistà, Antonino Rotilio, Claudio Licata, Mario
V. Fiorentino
From the Departments of Medical Oncology, Neurological
Sciences, Radiotherapy, Neuroradiology, and Neurosurgery, Azienda Ospedaliera,
Padova, and Department of Neurosurgery, Azienda Ospedaliera, Verona, Italy.
Address reprint requests to Alba A. Brandes, MD, Department of Medical
Oncology-Direzione, Azienda Ospedaliera, Via Giustiniani 2, 35100 Padova, Italy. Purpose.
A phase II study was conducted in patients with high-grade gliomas that recurred
after surgery plus radiotherapy and a first-line nitrosourea-based regimen.
Our aim was to investigate the efficacy of procarbazine (PCB) combined with
high-dose tamoxifen in relation to tumor control, toxicity, and time to
progression (TTP).
Patients and Methods.
Fifty-three patients were treated with procarbazine in repeated
30-day courses at 100 mg/m2/d plus tamoxifen 100 mg/d, with a 30-day interval
between courses.
Thirty-four patients had been pretreated with a first-line nitrosourea-based
chemotherapy regimen (group A), and 19 patients had also been pretreated with a
second-line chemotherapy regimen consisting of carboplatin and teniposide (group
B).
Twenty-one of the patients had also been procarbazine pretreated, whereas the
remaining 32 patients were not procarbazine pretreated.
Results.
The response was assessed in 51 patients, 28 of whom had glioblastoma multiforme
(GBM) and 23 of whom had anaplastic astrocytoma (AA).
There were two complete responses (CR) (4%) and 13 partial responses (PR)
(25.5%).
The overall response rate (CR + PR) was 29.5% (SE, 6.4; 95% confidence interval
[CI], 23 to 35.8).
Seventeen patients (32%) had stable disease (SE, 6.2; 95% CI, 21 to 33.6).
The median TTP was 13 weeks for patients with GBM and 33 weeks for patients with
AA (P = .006).
The median survival time (MST) was 27 weeks for patients with GBM and 57 weeks
for those with AA (P = .006).
Conclusion.
Combined PCB and tamoxifen as a second-line regimen gave a reasonably high
response rate in patients with heavily pretreated high-grade gliomas. However, although it resulted in an improvement in the patients' quality of life
and/or performance status, it was not followed by an increased TTP or MST.
Presented in part at the 33rd Annual Meeting
of the American Society of Clinical Oncology, Denver, CO, May 17-20,
1997.
©
1999 American Society for Clinical Oncology
|
